长春胺缓释胶囊对卒中后抑郁和神经功能恢复的作用观察

目的观察长春胺缓释胶囊对卒中后抑郁及神经功能恢复的治疗效果。方法将64例急性卒中后抑郁患者随机分为治疗组（34例）和对照组（30例），两组均接受常规药物治疗，治疗组同时加用长春胺缓释胶囊治疗。治疗前、治疗后6周、12周应用Hamilton抑郁量表（HAMD）24项评价抑郁状况，采用简易智能状态量表（MMSE）、美国国立卫生研究院卒中量表（NIHSS）和日常生活活动能力量表（ADL）15项评价患者的认知和神经功能状况。结果治疗后6周、12周时治疗组HAMD、NIHSS和ADL评分较对照组降低（均P〈0．05），MMSE评分较对照组增加（P〈0．05）。治疗组对卒中后抑郁的治愈率和总有效率分别为38％和91％，高于对照组的20％和73％（均P〈0．05）。结论长春胺缓释胶囊治疗卒中后抑郁有效，能改善患者情绪状态及促进神经功能恢复。

Observation on the effect of vinpocetine sustained-release capsules on post-stroke depression and recovery of neurological function

Objective To observe the effect of vinpocetine sustained-release capsules on post-stroke depression and recovery of neurological function. Methods A total of 64 patients with acute post-stroke depression were randomly divided into Vinpocetine sustained-release capsules group( 34 cases) and control group(30 cases). Conventional therapy was given to both groups. To the treatment group, vinpocetine sustained-release capsules was given at the same time. Depression status was assessed with Hamilton Rating Depression Scale(HAMD). Meanwhile ,Mimi-Mental State Examination( MMSE), National Institutes of Health Stroke Scale(NIHSS) and Activities of Daily Living(ADL)were given in to both groups. Results After 6 to 12 weeks' therapy, the total score of HAMD, NIHSS and ADL of Vinpoeetine group were significantly lower than the control group ( all P ＜ 0.05 ), MMSE score increased significantly ( P ＜ 0.05 ) in Vinpocetine group. The curative rate and effective rate of Vinpocetine group were 38％ and 91％. It was significantly higher than the 20％ and 73％ of the control group ( all P ＜ 0.05 ). Conclusion Vinpocetine sustainedrelease capsules was effective to treat post-stroke depression. It could improve the emotional state of patients and promote the recovery of neurological function.